 |
|
An In Vivo Assessment of Factor VIII Concentrates
G. Rock, MD, PhD;
Pauline Tittley, LCSLT;
Virginia Fuller, RT
JAMA. 1985;254(6):777-780.
Abstract
Replacement therapy for patients with hemophilia A requires that a specific dose of factor VIII be administered. Generally, these calculations involve the use of the manufacturer's stated dose in an equation. We have assessed factor VIII concentrates by in vitro techniques and found a considerable discrepancy (35%) between the stated and the measured contents. Confirmation of this discrepancy was obtained by in vivo assessment where posttransfusion recoveries corresponded to the measured rather than the stated contents of the vial. The half-disappearance time ranged from five to eight hours. The data suggest that constant monitoring of factor VIII preparations is necessary to ensure optimal treatment of patients with hemophilia A and help to explain the recent efforts by the Office of Biologics to achieve standardization.
(JAMA 1985;254:777-780)
Author Affiliations
From the Blood Transfusion Service, Canadian Red Cross, Ottawa Centre (Dr Rock and Mss Tittley and Fuller); and the Department of Medicine, University of Ottawa (Dr Rock).
Footnotes
Reprint requests to Medical Director, Blood Transfusion Service, Canadian Red Cross, Ottawa Centre, 85 Plymouth St, Ottawa, Ontario, Canada K1S 3E2 (Dr Rock).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A High-Potency, Single-Donor Cryoprecipitate of Known Factor VIII Content Dispensed in Vials
McLEOD et al.
ANN INTERN MED 1987;106:35-40.
ABSTRACT
Factor VIII Concentrates
Ratnoff
JAMA 1986;255:325-326.
ABSTRACT
Factor VIII Concentrates: Matching What You See With What You Get
Lusher
JAMA 1985;254:802-803.
ABSTRACT
|
